UBS Group
APGN

UBS Group’s Apexigen, Inc. Common Stock APGN Stock Holding History

UBS Group’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,376
Closed -$2.13K – 10184
2023
Q1 		$2.13K Sell
4,376
-5,657
-56% -$6.81K ﹤0.01% 8572
2022
Q4 		$6.82K Buy
10,033
+2,071
+26% +$4.04K ﹤0.01% 8981
2022
Q3 		$22K Buy
7,962
+4,614
+138% +$37.5K ﹤0.01% 7292
2022
Q2 		$34K Sell
3,348
-1,275
-28% -$12.9K ﹤0.01% 6285
2022
Q1 		$47K Buy
4,623
+474
+11% +$4.75K ﹤0.01% 6571
2021
Q4 		$42K Buy
4,149
+2,565
+162% +$25.6K ﹤0.01% 7084
2021
Q3 		$16K Sell
1,584
-999
-39% -$9.88K ﹤0.01% 7451
2021
Q2 		$26K Sell
2,583
-100
-4% -$991 ﹤0.01% 7093
2021
Q1 		$26K Buy
+2,683
New +$26.8K ﹤0.01% 7143

Other funds holding APGN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's APGN Position: Q2 2023 in Review

UBS Group sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2023, closing a stake of 4,376 shares — an estimated $2.13K sold.

UBS Group first reported a position in APGN in Q1 2021 and held it in 9 quarters. The position peaked at $47K in Q1 2022. 17 funds tracked by Wall St. Rank hold APGN as of Q2 2023.

  • UBS Group reported no remaining Apexigen, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 4,376 Apexigen, Inc. Common Stock shares in Q2 2023, an estimated $2.13K.
  • UBS Group first reported a position in Apexigen, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • UBS Group's Apexigen, Inc. Common Stock position peaked at $47K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.